US Patents Granted for ARIUS Antibodies

12-Mar-2007

ARIUS Research Inc. announced that it has been granted two new United States patents for antibodies within their CD63 program. Patent 7,175,846. covers anti-cancer antibodies in ARIUS' partnered program for melanoma, breast and prostate cancers and protects the valuable site on the disease target that the drug candidate binds to. The Company's FunctionFIRST(TM) platform uses a unique process to discover antibody drugs by identifying those that destroy cancer cells while leaving normal cells alone. In the process the antibodies can attach themselves to the cancer cell but they must hit the appropriate spot on the cell i.e. the "target on the target", in order to destroy it. ARIUS' patent strategy has successfully captured the discovery process, the antibody drug molecules and now the spot on the target that is key to causing the cancer cell's destruction.

Patent 7,186,808 covers a second antibody within this program that kills breast and prostate cancer cells. The patent also covers the use of the antibody as a treatment for breast cancer.

Other news from the department research and development

More news from our other portals

So close that even
molecules turn red...

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world
Topic world Antibodies

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous